Centrosome-related Service for Ovarian Cancers

Ovarian cancers are a group of diseases originate from ovaries or related areas of the fallopian tubes and the peritoneum. Centrosome is in charge of cell division, and the abnormality of centrosome causes chromosomal instability, which leads to aneuploidy, the biomarker of human cancers. CD BioSciences provides centrosome-related service with our advanced technology and experienced experts for meeting our global customer's demands in centrosome research and the therapeutic development of ovarian cancers.

Relevance between Centrosome & Ovarian Cancers

Centrosome abnormality (CA) is a common feature of most human cancer cell lines, which contains the numeric abnormality and structural abnormality, such as increase in centrosome number and size, accumulation of excess pericentriolar material and supernumerary centrioles. Aneuploidy is a hallmark of cancer tissue and is a consequence of chromosomal instability. The centrosome abnormality is the most prominent cause of chromosome instability (CIN) during mitosis, which results in aneuploidy.

Epithelial ovarian cancers (EOCs) are among the most deadly cancers in women worldwide, and EOCs are hard to treat due to late diagnosis and poor patient stratification. Unlike the frequently observed centrosome amplification in most tumor tissues, such as breast cancer and colon carcinoma. Healthy ovarian tissues contain one centrosome in each cell, while in the EOC cells, centrosome loss can be frequently observed. What's more, the frequency of centrosome abnormalities increases along with the tumor stage.

CAs in ovarian cancers (Morretton JP, et al., 2022)

The centrosome abnormality can be assessed by digital analysis of fluorescence confocal microscopy images. This method can greatly assist in studying centrosome abnormality during tumor progression, and rapidly screen for patients at high risk of clinically aggressive cancers. What's more, the evolution of centrosome abnormalities during cancer initiation and progression and the predominance of centrosome abnormality in the different tumor stages can also be detected with this method. Here is the list of the centrosome abnormality cases in normal ovarian tissues and tumor ovarian tissues.

CAs in Ovarian Tissues

Our Services

Due to the frequent observation of centrosome abnormalities in ovarian cancers, the centrosome and centrosomal proteins are considered as promising therapeutic target. For study the mechanisms of centrosome abnormalities in ovarian cancer and revealing the therapeutic targets, CD BioSciences offers centrosome-related services including but not limited as follows.

Why Choose Us

Professional Team

Comprehensive Platform

High Efficiency

One-stop Service

With skilled and experienced genomics and cytology experts, state-of-the-art equipment and advanced technology, CD BioSciences offers customer all over the word services related to fields of centrosomal research. Our one-stop service program is your best assistant to accelerate you process of centrosomal research. Please feel free to contact us and get started with our high-quality services.

Reference

1. Morretton JP, et al., A catalog of numerical centrosome defects in epithelial ovarian cancers. EMBO Mol Med. 2022 Sep 7;14(9):e15670.

Our services are for research use only and not for any clinical use.